Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.555 USD | -3.08% | +1.07% | +11.85% |
05-14 | Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating | MT |
05-14 | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.85% | 484M | |
+33.52% | 50.85B | |
-0.06% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.17% | 26.11B | |
-22.04% | 19.13B | |
+8.51% | 13.05B | |
+28.02% | 12.16B | |
+24.57% | 12.08B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $26 From $25, Maintains Overweight Rating